STATERA BIOPHARMA INC (STAB) Stock Price, Quote, News and Overview
NASDAQ:STAB - Nasdaq - US8575611046 - Common Stock - Currency: USD
STAB Quote, Performance and Key Statistics
0.0911
-0.01 (-5.2%)
The current stock price of STAB is 0.0911 USD. In the past month the price decreased by -20.09%. In the past year, price decreased by -95.38%.
STAB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About STAB
Company Profile
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is headquartered in Fort Collins, Colorado and currently employs 46 full-time employees. The company went IPO on 2006-07-21. The firm is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers. Its Advanced Immunomodulating Multi-Component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include R4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200 and STAT-600 AIMS programs. Its STAT-200 program include STAT-201 is focused on treatment of Crohn’s disease. The firm has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205).
Company Info
STATERA BIOPHARMA INC
2537 Research Boulevard, Suite 201
Fort Collins COLORADO US
CEO: Christopher Zosh
Employees: 46
Company Website: https://www.staterabiopharma.com/
Phone: 18886138802.0
STATERA BIOPHARMA INC / STAB FAQ
What is the stock price of STATERA BIOPHARMA INC today?
The current stock price of STAB is 0.0911 USD. The price decreased by -5.2% in the last trading session.
What is the ticker symbol for STATERA BIOPHARMA INC stock?
The exchange symbol of STATERA BIOPHARMA INC is STAB and it is listed on the Nasdaq exchange.
On which exchange is STAB stock listed?
STAB stock is listed on the Nasdaq exchange.
What is STATERA BIOPHARMA INC worth?
STATERA BIOPHARMA INC (STAB) has a market capitalization of 4.98M USD. This makes STAB a Nano Cap stock.
How many employees does STATERA BIOPHARMA INC have?
STATERA BIOPHARMA INC (STAB) currently has 46 employees.
What are the support and resistance levels for STATERA BIOPHARMA INC (STAB) stock?
STATERA BIOPHARMA INC (STAB) has a resistance level at 0.1. Check the full technical report for a detailed analysis of STAB support and resistance levels.
Should I buy STATERA BIOPHARMA INC (STAB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of STAB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of STAB, evaluating the profitability, health, valuation and growth aspects
- STATERA BIOPHARMA INC (STAB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- STATERA BIOPHARMA INC (STAB) Sales and EPS estimates to see what analysts future expectations are.
- STATERA BIOPHARMA INC (STAB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- STATERA BIOPHARMA INC (STAB) Insider and Institutional Ownership to learn about the owners and their transactions.
- STATERA BIOPHARMA INC (STAB) Stock Chart to make your own analysis
- STATERA BIOPHARMA INC (STAB) Latest news and press-releases to stay up to date.
Does STATERA BIOPHARMA INC (STAB) stock pay dividends?
STAB does not pay a dividend.
When does STATERA BIOPHARMA INC (STAB) report earnings?
STATERA BIOPHARMA INC (STAB) will report earnings on 2023-03-29.
What is the Price/Earnings (PE) ratio of STATERA BIOPHARMA INC (STAB)?
STATERA BIOPHARMA INC (STAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.72).
What is the Short Interest ratio of STATERA BIOPHARMA INC (STAB) stock?
The outstanding short interest for STATERA BIOPHARMA INC (STAB) is 0.18% of its float. Check the ownership tab for more information on the STAB short interest.
STAB Technical Analysis
STAB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to STAB. Both the profitability and financial health of STAB have multiple concerns.
STAB Financial Highlights
Over the last trailing twelve months STAB reported a non-GAAP Earnings per Share(EPS) of -1.72. The EPS decreased by -71.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |